Saturday 17 October 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.

177.96 11.30 −5.97%

Follow RVMD

Alert me

Market cap: $40.6B
P/E: 0.0×
Fwd P/E: −11.9×
Dividend yield: —
F-score: 4/9
Altman Z: 7.73
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 154.34

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	7	5	3	—	9	2	1	9	—	3	15	—

Insider Ownership 8.47%

Capital & Financial Ratios $m

Market Cap 40,570.00

Revenue 26.91

Net Income (1,768.28)

Free Cash Flow (1,232.13)

Net Debt (2,901.99)

Current Ratio 11.38

Debt/Equity 0.40

P/E ratio 0.00

Fwd P/E (11.90)

P/S ratio 1,394.67

P/B ratio 14.40

Past 5Y EPS Growth —

This Y EPS Growth (59.42%)

Next Y EPS Growth 37.96%

Next Y revenue growth (97.01%)

Next 5Y EPS Growth 23.71%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 95.41%

10-year low 10-year high

P/B against its own 10 years 92.10%

10-year low 10-year high

EV/Sales against its own 10 years 95.32%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,853	2,289	2,026	3,938
Receivables	1	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,879	2,328	2,075	4,028

	2023	2024	2025	Q'26
Payables	62	54	65	88
ST’ Debt	—	—	—	—
Other	—	—	—	—
	144	164	290	354

Compound Annual Growth %

	10y	5y	3y
Sales	—	(10.50%)	(35.41%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	28.01%	33.53%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	7	4	—	1	12
’22	8	9	3	15	35
’21	10	9	1	9	29
’20	12	10	13	9	43
’19	13	12	13	12	50

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(354)	(387)	—	—	—
’25	(194)	(222)	(207)	(274)	(898)
’24	(161)	(128)	(130)	(138)	(557)
’23	(62)	(67)	(100)	(121)	(351)
’22	(55)	(56)	(52)	(62)	(224)
’21	(37)	(34)	(37)	(39)	(147)
’20	(28)	(20)	(27)	(25)	(100)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(356)	(390)	—	—	—
’25	(198)	(229)	(211)	(276)	(914)
’24	(164)	(131)	(134)	(140)	(568)
’23	(64)	(68)	(103)	(123)	(358)
’22	(57)	(58)	(55)	(65)	(235)
’21	(41)	(35)	(37)	(40)	(154)
’20	(29)	(20)	(28)	(26)	(103)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.29)	(3.06)	—	—	—
’25	(1.13)	(1.31)	(1.61)	(1.86)	(5.95)
’24	(0.70)	(0.81)	(0.94)	(1.12)	(3.58)
’23	(0.72)	(0.92)	(0.99)	(1.14)	(3.86)
’22	(0.78)	(0.82)	(0.87)	(0.63)	(3.08)
’21	(0.53)	(0.60)	(0.72)	(0.71)	(2.57)
’20	(0.74)	(0.46)	(0.42)	(0.52)	(2.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	17.35	21.78	14.08	15.44	25.93	29.17	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	47.83	56.18	27.49	35.60	62.40	81.97
People
People	Employees	—	—	90	95	125	188	246	378	534	883
	Revenue/emp, $m	—	—	0.22	0.53	0.34	0.16	0.14	0.03	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	20	50	43	29	35	12	—	—
	Gross margin, %	—	0.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—
	EBT	—	(31)	(42)	(52)	(109)	(187)	(249)	(440)	(601)	(1,131)
	EBT margin, %	—	0.00	(207.24)	(103.99)	(252.50)	(636.58)	(704.14)	(3,798.71)	0.00	0.00
	Net income	—	(31)	(42)	(48)	(108)	(187)	(249)	(436)	(600)	(1,131)
	Depreciation	—	1	2	3	8	10	7	(13)	(33)	(11)
Per share, $
Per share, $	Revenue	—	0.00	8.77	18.05	0.78	0.40	0.44	0.10	0.00	0.00
	Earnings	—	(18.07)	(18.18)	(17.19)	(2.01)	(2.57)	(3.08)	(3.86)	(3.58)	(5.95)
	Cash flow	—	(14.60)	0.53	(17.89)	(1.82)	(2.02)	(2.78)	(3.10)	(3.32)	(4.72)
	Capex	—	(0.91)	(0.65)	1.30	(0.05)	(0.09)	(0.13)	(0.07)	(0.06)	(0.08)
	Free cash flow	—	(15.51)	(0.12)	(16.59)	(1.88)	(2.11)	(2.92)	(3.17)	(3.38)	(4.81)
	Book value	—	0.00	42.04	55.01	8.65	8.28	8.50	16.14	13.50	8.58
	Shares, m	—	2	2	3	55	73	81	113	168	190
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	P/S	—	—	1.60	1.60	50.54	62.35	52.30	118.70	—	—
	P/B	—	—	0.00	0.00	4.58	3.04	2.70	1.75	—	—
	EV/Sales	—	—	(0.85)	(0.85)	40.96	44.77	35.68	51.96	—	—
	EV/FCF	—	—	0.93	0.93	(17.09)	(8.56)	(5.37)	(3.90)	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(25)	1	(50)	(100)	(147)	(224)	(351)	(557)	(898)
	Capex	—	(2)	(1)	4	(3)	(7)	(11)	(8)	(10)	(16)
	Free cash flow	—	(27)	0	(46)	(103)	(154)	(235)	(358)	(568)	(914)
Balance, $m
Balance, $m	Working capital	—	2	55	91	407	529	598	1,735	2,164	1,785
	Total debt	—	—	0	0	29	60	57	—	—	268
	Net debt	—	(9)	(70)	(123)	(412)	(517)	(588)	(1,853)	(2,289)	(1,757)
	Shareholders’ equity	—	—	97	153	475	603	685	1,826	2,265	1,631
Returns, %
Returns, %	ROA	—	(37.00)	(57.24)	(31.65)	(28.02)	(28.66)	(32.09)	(30.37)	(25.98)	(46.06)
	ROIC	—	0.00	(93.10)	(113.59)	(109.95)	(136.74)	(165.26)	0.00	0.00	0.00
	ROE	—	39.62	55.43	47.44	(68.54)	(34.74)	(38.63)	(34.75)	(29.33)	(58.07)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Dec 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARGX argenex SE	$53.2B	29.6×	32.4×	+59.46% (above 0%: growing)	+88.56% (above 0%: growing)	+537.51% (above 0%: growing)	90.60%	32.04%	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
Median of peers	$28.0B	34.5×	27.2×	+27.24%	+39.71%	+74.75%	90.18%	19.41%

All 614 Biotechnology stocks →

Revolution Medicines, Inc. (RVMD) key facts

Concern: Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
Revolution Medicines, Inc. (RVMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RVMD traded at $177.96, a market capitalization of $40.6 billion.
Return on equity was −58.1% and debt-to-equity 0.40.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 7.73 (safe zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.